MGI Tech Co., Ltd.
Shenzhen, China (ots/PRNewswire)
MGI Tech Co.Ltd. (MGI), a company dedicated to building core tools and technologies to guide LEAD Life Science, recently announced that as part of the “Million Microbiome of Humans Project (MMHP)” officially launched in ARM 2019 a total of 60,000 samples were sequenced from 21 institutes and over 10 participating nations across Europe.
The project was launched as a joint effort between Sweden’s Karolinska Institute, the Shanghai National Clinical Research Center for Metabolic Diseases in China, the University of Copenhagen in Denmark, the Technical University of Denmark and MetaGenoPolis at the National Research Institute for Agriculture, Food and Environment (INRAE) in France , and the Latvian Biomedical Research and Study Center. Based on MGI’s core DNBSEQ™ technology, MMHP aims to sequence and analyze microbial DNA from one million human samples to create a microbiome map of the human body, thereby building the world‘s largest human microbiome database.
“Countless studies have highlighted the importance of the microbiome in human health and disease. However, our knowledge of the composition of the microbiome in different parts of the body across countries, age, gender and in relation to human health and disease remains limited,” said Duncan Yu, President of MGI “Give the microbiology community access to MGI’s innovative sequencing technology. Despite a brief disruption due to the COVID-19 pandemic, we are pleased to see such a monumental milestone after only four years in the project.”
The rise of microbial metagenomic sequencing
Since the first description of the human microbiome was published in 2010, the scope of the human microbiome has rapidly changed from sampling hundreds to thousands of individuals. Advances in genome sequencing have allowed researchers to better characterize the composition of the microbiome by identifying uncultivable microbes. It has also given them the opportunity to study how the microbiome affects the development of some cancers and can influence drug responses.
Metagenomics coupled with high-throughput sequencing technologies have revolutionized microbial ecology. Today, metagenomic sequencing has become a powerful and popular tool for identifying and classifying complex microbial communities. It facilitates the accelerated discovery of new markers that translate into virulence or antibiotic resistance, as well as the de novo discovery and characterization of novel species, and the assembly of new genomes. Besides human microbiome, it is very applicable in studies of agricultural microbiome, environmental microbiome studies, pathogen monitoring and identification, and monitoring of antimicrobial resistance genes.
In fact, the global metagenomic sequencing market was estimated to reach USD 1.86 billion in revenue in 2022 and is expected to grow to USD 4.33 billion by 2027 growing at a CAGR of 18.4% during the forecast period. Specifically, Europe and Africa account for around 29.7% of the global market, second only to North America at 45.6%. Thanks to continued technological innovations in high-throughput sequencing platforms, the market for metagenomic sequencing in Europe and Africa is expected to grow from USD 551.7 million in 2022 to USD 1.29 billion in 2027, opening enormous market opportunities and kick-starting local institutions will give to invest and get involved.
A streamlined workflow with state-of-the-art technology from MGI
Equipped with the innovative laboratory systems from MGI, the MMHP Consortium guarantees high throughput processes, extreme precision and high-quality data output. The dedicated, centralized workflow begins with sample transfer on the high-throughput, automated MGISTP-7000* Sample Transfer System. Then, nucleic acid extraction and library preparation is performed on the MGISP-960 high-throughput automated sample preparation system, a flexible and fully automated workstation capable of processing 96 samples per run. The fully automated operational design of MGISP-960 enables DNA extraction of 50,000 samples per year and library preparation of 25,000 samples per year. MGISP-Smart 8, the professional automated pipetting robot, is equipped with 8 independent pipetting channels and can be used for pooling, normalization and DNB creation. Finally, the DNBSEQ-T7* ultra-high-throughput sequencer and the versatile DNBSEQ-G400* benchtop sequencer enable efficient, productive, and streamlined sequencing.
“We attach great importance to data quality, as well as costs and time. After comparing MGI’s DNBSEQ™ technology to other sequencing technologies, we are confident that MGI’s products meet high industry standards and provide a very good user experience,” commented Professor Lars Engstrand, Research Director of the Center for Microbial Translational Research ( CMTR) at Karolinska Institutet.”The MGI platforms have enabled our team to transition our original microbiology research from 16SrRNA gene amplicon sequencing to shotgun metagenome sequencing. I look forward to the launch of more devices, and very large ones.” Projects as the human microbiome emerges as a critical diagnostic and treatment tool in precision medicine.”
The next chapter in microbiomics
“Microbiomics will be part of precision medicine in the future and data from the microbiome biobank resulting from MMHP will be used for therapeutic research and development,” said Professor Stanislav Dusko Ehrlich from University College London, UK Public and private institutions and more than 10 countries are involved in MMHP, we are actively looking for additional research groups to participate in this pioneering international microbiology research partnership and help create the world‘s largest open-access database of human microbiomes.”
Since the inception of MMHP, MGI has played an important role in providing the program with cutting-edge research platforms and technologies. The project is now entering the second phase of sequencing and analysis of a total of one million samples and welcomes further exchange and involvement of relevant organizations to jointly promote research and applications of cutting-edge translational medicine in the field of the microbiome.
Information about MGI
MGI Tech Co.Ltd. (MGI), headquartered in Shenzhen, aims to develop key tools and technologies to advance life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on research and development, production and sales of sequencing instruments, reagents and related products in support of life science research, agriculture, precision medicine and healthcare. MGI is a leading manufacturer of high-throughput clinical gene sequencers*. Its multi-omics platforms include genetic sequencing*, as well as medical imaging and laboratory automation. MGI’s mission is to develop and advance advanced life science tools for future healthcare. For more information, visit the MGI website or contact us at TwitterLinkedIn oder YouTube.
* Unless otherwise informed, the sequencing reagents for StandardMPS and CoolMPS and sequencers for use with such reagents are not available in Germany Sweden, Spain, UK, Italy Czech Republic, Switzerland, Hong Kong and China (CoolMPS is available in Hong Kong).
*For research use only. Not for use in diagnostic procedures (unless specifically stated).
View original content: https://www.prnewswire.com/news-releases/mgi-ermoglicht-den-abschluss-von-fast-60-000-proben-fur-das-projekt-the-million-microbiome-of-humans-301824778.html
Press contact:
Wenhui Liu,
[email protected]
Original content from: MGI Tech Co., Ltd., transmitted by news aktuell